Phl.Nz
PHL.NZ operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services, primarily generating revenue through its operations in this field.
Business. PHL.NZ operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services, primarily generating revenue through its operations in this field.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
PHL.NZ operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services, primarily generating revenue through its operations in this field.
The company maintains a capital structure with a debt-to-equity ratio of 1.19, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with free cash flow of NZD 6.7 million and operating cash flow of NZD 3.4 million, suggesting the company generates sufficient cash to cover operations and some debt obligations. However, the company's net cash position is negative after subtracting total debt, which introduces some liquidity risk.
In terms of profitability, PHL.NZ reports a return on equity (ROE) of 17.41% and a return on assets (ROA) of 3.97%. These figures are strong for ROE but modest for ROA, indicating that the company is effectively using equity to generate returns but is less efficient in utilizing its total assets. The company's operating income of NZD 9.5 million and net income of NZD 6.8 million reflect a healthy margin, though the ROA suggests there is room for improvement in asset utilization.
PHL.NZ's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of segment and geographic diversification could expose the company to higher concentration risk, particularly if its primary market experiences downturns.
The company's growth trajectory is not clearly defined in the available data, as the analyst estimates for revenue and EPS are not available or are zero. However, the company's operating and free cash flows suggest a stable operational performance, which could support future growth initiatives. The capital expenditure of NZD -285,000 indicates a reduction in capital spending, which may be a strategic decision to preserve cash or a sign of reduced investment in growth projects.
The risk assessment for PHL.NZ highlights a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, indicating potential challenges in meeting short-term obligations without additional financing. The dilution risk is low, suggesting that the company is not expected to issue a significant number of new shares in the near term, which is supported by the current share count and the absence of dilution-related disclosures in the available data.
Recent events and disclosures for PHL.NZ are limited in the provided data. The company's financial snapshot does not include recent filings or transcripts, and the analyst estimates for revenue and EPS are either not available or zero. This lack of recent data may limit the ability to assess the company's current performance and strategic direction.
- PHL.NZ has a strong return on equity (17.41%) but a modest return on assets (3.97%), indicating effective use of equity but less efficient asset utilization.
- The company's liquidity position is medium, with free cash flow of NZD 6.7 million and operating cash flow of NZD 3.4 million, but it has a negative net cash position after subtracting total debt.
- PHL.NZ's revenue is concentrated in a single business segment, with no geographic diversification provided, which could increase concentration risk.
- The company's growth trajectory is not clearly defined in the available data, and recent events or disclosures are limited, making it difficult to assess current performance and strategic direction.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- PHL.NZ Market data — financials · 2026-05-28
- Promisia Healthcare Ltd Market data — analyst estimates · 2026-05-28